Guides

Does Medicare Cover GLP-1 Drugs? What CMS Says as of October 2026

October 30, 2026

Educational only. Not medical advice. Talk to your doctor.

Short answer: As of October 30, 2026, Medicare covers certain GLP-1 drugs for weight management through a temporary CMS program called the Medicare GLP-1 Bridge, which began July 1, 2026, for people with Medicare Part D who meet eligibility rules. Eligible people pay a $50 copayment for a one-month supply. GLP-1 drugs for type 2 diabetes, sleep apnea and some liver disease are handled through regular Part D plans. Rules can change, so check Medicare.gov or call 1-800-MEDICARE for the current details. This page reports what the government pages say and is not insurance advice.

What is the Medicare GLP-1 Bridge?

The Centers for Medicare & Medicaid Services (CMS) describes it as “a short-term demonstration run by CMS” that will “provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs.” It runs “between July 1, 2026, and December 31, 2027.” Medicare.gov says prior authorization is valid through December 31, 2027, unless you change GLP-1s.

Which drugs does the Bridge cover?

According to Medicare.gov, starting July 1, 2026, Medicare covers:

  • Foundayo® (orforglipron) tablets
  • Wegovy® (semaglutide), injection or tablet
  • Zepbound® (tirzepatide), KwikPen only

Medicare.gov says “the program doesn’t cover single-dose Zepbound vials or pens.” The Bridge is for weight management. For how semaglutide and tirzepatide compare, see Tirzepatide vs semaglutide. For how these brands differ, see Ozempic vs Wegovy and Mounjaro vs Zepbound.

Who is eligible?

Medicare.gov says you must be 18 or older, have Part D drug coverage, and meet one of these when starting:

BMIExtra condition needed
35 or higherNone
30 or higherOne of: diastolic heart failure, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher
27 or higherOne of: prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms

Your provider must also complete a prior authorization and certify use as part of a lifestyle program focused on diet and exercise. People who already get GLP-1 drugs covered through their Part D plan are not part of the Bridge.

What does it cost?

Medicare.gov says: “You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).” The page also says the copayment does not count toward your Part D deductible or out-of-pocket limit, and that Extra Help cannot lower it.

What about GLP-1 drugs for diabetes, sleep apnea or liver disease?

Medicare.gov and CMS say people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or fatty liver disease (CMS says noncirrhotic MASH with moderate to advanced fibrosis) are not eligible for the Bridge because those conditions are covered under Part D. Medicare.gov says “your Medicare drug plan should cover GLP-1 medications to treat these conditions.”

That lines up with the labels’ approved uses. The Zepbound label lists treating moderate to severe obstructive sleep apnea in adults with obesity, and the Wegovy label lists noncirrhotic MASH with moderate to advanced liver fibrosis. Which drugs and which uses your plan covers is set by the plan. Ask the plan about its drug list and prior authorization steps.

What if you are not on Medicare?

The Bridge applies to people with Medicare Part D. For other insurance, coverage depends on the plan, and a plan’s member services line can tell you whether a drug is covered, whether prior authorization applies and what you would pay. For people without coverage, Medicare.gov lists other savings options, including manufacturer assistance, state programs, mail-order pharmacies and TrumpRx.gov. Check each option’s own terms.

How can you prepare for the coverage conversation?

Your provider may need to show the BMI and condition when you started and details of your lifestyle program. A running record of shot dates and visits can make that easier to pull together. Weeko, a shot tracker coming to iPhone and Android, is being built around that kind of simple log. It is a logbook, not medical or insurance guidance.

When to call your doctor or Medicare

Call 1-800-MEDICARE (1-800-633-4227; TTY 1-877-486-2048) with coverage questions. Ask your prescriber, not the plan, about whether a medicine is right for you, and ask before switching medicines because of coverage.

Related guides

Sources

  1. Weight loss drugs, Medicare.gov
  2. Medicare GLP-1 Bridge: Information for Part D Plans, Centers for Medicare & Medicaid Services
  3. Zepbound (tirzepatide) prescribing information, DailyMed
  4. Wegovy (semaglutide) prescribing information, DailyMed

Ozempic®, Wegovy®, Rybelsus® are trademarks of Novo Nordisk A/S; Mounjaro®, Zepbound®, Foundayo® are trademarks of Eli Lilly and Company. Weeko is not affiliated with or endorsed by these companies.